{"page_content": "22      KODIAK 2021 ESG REPORT BACK TO CONTENTS >>\nPeople and Communities\nOUR COMPANY CULTURE \nOur success continues to be driven by our community of colleagues and valued \npartner organizations who share our dedication and commitment to improving the \nlives of patients with retinal disease. We are creating a culture of curiosity, creativity, \ncompassion and courage that we believe is critical to our success. \nEngaged, talented and collaborative colleagues will help propel Kodiak at this \nkey juncture in our evolution. As we begin to see data from our six registrational \nclinical trials, we expect to gain greater insight into the potential of our lead product \ncandidate, KSI-301, to meaningfully help patients. The trajectory of our growth \nwill be influenced by this insight and our team will need to be ready to meet the \nopportunities and challenges presented.\nBuilding a globally integrated ophthalmology medicines company \nis an ambitious goal that requires us to continue to recruit and \ncultivate talent and capabilities both within our team at Kodiak \nand with qualified partners. \nWe are working hard to attract and retain people with the right skills and mindset  \nto help deliver on our important mission. \n", "metadata": {"source": "NASDAQ_KOD_2021.pdf", "page": 21, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}